Shuttle Pharmaceuticals (SHPH) - חוב לטווח ארוך להון

The Shuttle Pharmaceuticals (SHPH) price chart on the GURU.Markets platform demonstrates the 0.01 metric. The business relies on unique patents, avoiding price wars due to a lack of approved analogs. Shuttle Pharmaceuticals is developing a closed radiation therapy network, tying medical centers to its proprietary protocols. However, geopolitical tensions and sanctions are complicating the logistics of biomaterials, which is slowing down the conduct of global studies in Europe.

Fundamental issuer selection is based on an analysis of debt sustainability and capital structure. This ratio compares liabilities with a maturity of over one year against the company's equity. For Shuttle Pharmaceuticals (SHPH), low leverage is supported by the humanitarian status of its developments, which eliminates geopolitical risks and sanctions pressure. A reduction in this metric minimizes financial threats, although it may limit growth rates. The history of long-term debt-to-equity clearly demonstrates the current balance between security and profitability.